Ligand Pharmaceuticals Inc (LGND)
Cost of Revenue
$4.12M
TTM · Period ending: · USD
LGND Cost of Revenue
Latest reported$4.12Mperiod ending
Latest reported$4.12Mperiod ending
LGND TTM Cost of Revenue ($24.70M → $4.12M)
TTM cost of revenue
High-resolution chart · PNG
LGND cost of revenue history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Cost of Revenue (USD) |
|---|---|
| 4,120,500 | |
| 3,813,500 | |
| 6,587,500 | |
| 35,413,000 | |
| 23,088,000 | |
| 4,855,000 | |
| 11,074,000 | |
| 9,901,000 | |
| 891,000 | |
| 17,886,000 | |
| 10,535,000 | |
| 30,485,000 | |
| 41,153,000 | |
| 51,845,000 | |
| 52,827,000 | |
| 43,197,000 | |
| 40,490,000 | |
| 58,722,000 | |
| 62,176,000 | |
| 61,931,000 | |
| 56,838,000 | |
| 33,889,000 | |
| 30,419,000 | |
| 20,617,000 | |
| 17,411,000 | |
| 12,172,000 | |
| 11,347,000 | |
| 12,365,000 | |
| 10,678,000 | |
| 9,407,000 | |
| 6,337,000 | |
| 5,120,000 | |
| 6,045,000 | |
| 5,814,000 | |
| 5,367,000 | |
| 6,525,000 | |
| 5,139,000 | |
| 4,956,000 | |
| 5,570,000 | |
| 3,558,000 | |
| 3,809,000 | |
| 5,689,000 | |
| 5,808,000 | |
| 8,926,000 | |
| 9,172,000 | |
| 7,758,000 | |
| 9,135,000 | |
| 6,450,000 | |
| 7,492,000 | |
| 7,520,000 | |
| 5,732,000 | |
| 6,743,000 | |
| 4,888,000 | |
| 4,109,000 | |
| 3,601,000 | |
| 3,331,000 | |
| 3,351,000 | |
| 4,539,000 | |
| 4,909,000 | |
| 2,851,000 | |
| 2,148,000 | |
| 525,000 | |
| 0 | |
| -15,235,000 | |
| 0 | |
| 0 | |
| 0 | |
| 15,235,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 5,874,000 | |
| 11,674,000 | |
| 21,940,000 | |
| 31,680,000 | |
| 34,114,000 | |
| 38,121,000 | |
| 38,522,000 | |
| 39,847,000 | |
| 41,583,000 | |
| 42,787,000 | |
| 42,046,000 | |
| 39,804,000 | |
| 38,427,000 | |
| 35,981,000 | |
| 33,821,000 | |
| 31,618,000 | |
| 28,470,000 | |
| 25,551,000 | |
| 22,466,000 | |
| 20,306,000 | |
| 19,173,000 | |
| 17,172,000 | |
| 14,631,000 | |
| 12,074,000 | |
| 15,554,000 |